Company Overview - Longevity Health Holdings, Inc. (XAGE) focuses on advancing human longevity and healthy aging through regenerative bio-aesthetics, diagnostics, and nutrition [1][3] - The company offers two regenerative technologies: Carmell Secretome™ and Elevai Exosomes™, aimed at improving skin and hair health [3] Recent Financial Activity - XAGE successfully sold 479,621 shares of common stock at an average price of $4.08 per share, generating gross proceeds of approximately $1.96 million before fees and expenses [1] - This financing extends XAGE's cash runway into Q1 FY26, assuming no growth beyond the pro forma consolidated FY24 sales and not factoring in the planned merger with 20/20 [2] Strategic Developments - The company is moving forward with a planned merger with 20/20 BioLabs, which develops innovative laboratory tests for chronic disease risk management [3][4] - The successful ATM offering reflects continued investor confidence in XAGE's vision and growth strategy, as stated by the CEO Rajiv Shukla [3]

Core Viewpoint - Longevity Health Holdings, Inc. has received approval from the Nasdaq Hearings Panel to continue its listing on Nasdaq, contingent upon meeting initial listing rules following its proposed merger with 20/20 BioLabs by September 2, 2025 [1][3]. Company Overview - Longevity Health Holdings focuses on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition [1][4]. - The company offers two regenerative technologies: Carmell Secretome™ and Elevai Exosomes™, aimed at improving skin and hair health [4]. Merger Details - The proposed merger with 20/20 BioLabs includes a strategic plan to effect a 1-for-30 reverse stock split to meet Nasdaq's listing requirements [2]. - The S-4 registration statement for the merger was filed on May 8, 2025, and the reverse stock split was executed on May 12, 2025 [2]. 20/20 BioLabs Overview - 20/20 BioLabs specializes in developing innovative laboratory tests for early detection and management of chronic disease risks, including a multi-cancer early detection blood test available in the U.S. [5]. - The company plans to introduce a new blood test for monitoring chronic inflammation, which is linked to several leading causes of death in America [5].

Core Insights - Longevity Health Holdings, Inc. (XAGE) focuses on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition [2] - The company announced a merger agreement with 20/20 BioLabs, which will continue as a wholly owned subsidiary post-merger [4] Business Updates - 20/20 develops laboratory tests for early detection and management of chronic disease risk, including a multi-cancer early detection blood test and a new blood test for monitoring chronic inflammation [1][4] - XAGE reported Q1 sales of approximately $663,000, an 8% increase year-over-year, while 20/20 reported sales of approximately $562,000, a 15% increase year-over-year [4] - A reverse stock split of 1 for 30 was completed on May 12, 2025, with trading at the adjusted price starting on May 14, 2025 [4] Product Launches - XAGE plans to launch a medicated cleanser for use in physicians' offices and MedSpas, targeting 20/20's customer base [4] - 20/20 is set to launch a lab test measuring inflammatory biomarkers, which will also be marketed to XAGE's customer base [4] - An initiative with Giant Food will offer 20/20's multi-cancer test in select stores, with potential expansion to include tests for biomarkers linked to pro-inflammatory foods [4] Financial Considerations - XAGE is evaluating options for additional financing and anticipates announcing a primary investment in Q2 2025 [4]

Core Viewpoint - Longevity Health Holdings, Inc. has announced a reverse stock split at a ratio of 1-for-30, which was approved by stockholders and is set to take effect on May 12, 2025 [1][2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 30.1 million to about 1 million shares [3]. - The effective time for the reverse stock split is set for May 12, 2025, with trading on a split-adjusted basis expected to begin on May 14, 2025 [2][3]. - No fractional shares will be issued; any fractional shares will be rounded up to the nearest whole share [4]. Group 2: Stockholder and Trading Information - Registered stockholders holding shares in book-entry form will not need to take action to receive post-split shares, while those in brokerage accounts will have their positions automatically adjusted [4]. - Proportional adjustments will be made to the number of shares issuable upon exercise of outstanding stock options and warrants, as well as the exercise prices [5]. Group 3: Company Overview - Longevity Health Holdings, Inc. focuses on bio-aesthetics, particularly in longevity and healthy aging, with product lines including Carmell Secretome™ and Elevai Exosomes™ [7]. - The company sells its products through business-to-business, direct-to-consumer, and distributor sales channels in the United States [7].

Core Viewpoint - Longevity Health Holdings, Inc. has announced a merger with 20/20 BioLabs, Inc. in an all-stock transaction aimed at enhancing its diagnostics capabilities and addressing chronic disease risks in America [1][4]. Company Overview - Longevity Health Holdings focuses on human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition [1][10]. - 20/20 BioLabs specializes in laboratory tests for early detection and management of chronic disease risk, offering the only multi-cancer early detection blood test available for under $200 [9][10]. Merger Details - The merger is expected to close in the third quarter of 2025, pending customary closing conditions and stockholder approvals [7]. - Post-merger, 20/20 stockholders will own approximately 50.1% and Longevity stockholders will own approximately 49.9% of the combined company [7]. - The combined company will continue trading on Nasdaq under the symbol "XAGE" [1]. Financial Implications - The merger is projected to double Longevity's fiscal year 2025 revenue forecast from approximately $3-4 million to approximately $7-8 million [6][7]. - The combined company is expected to have a post-merger equity valuation of approximately $99 million, with 20/20's pre-money valuation at around $50 million [6][7]. - Anticipated operational savings and synergies are expected to exceed $1 million in fiscal year 2025 [6]. Strategic Goals - The merger aligns with Longevity's strategy to expand its footprint in diagnostics and enhance synergies with its existing product portfolio [1][4]. - The combined company aims to address the epidemic of chronic disease in America under the "Healthy Aging, Inside and Out™" initiative [1]. Management Structure - The management team of the combined company will be mutually selected, with a Board of Directors comprising three members from each company [8].